Trends in Antiepileptic Drug Use in Pharmacoresistant Epilepsy

Background: Antiepileptic drugs are the cornerstone of treatment in patients with epilepsy. AIM: to examine the spectrum of antiepileptic drugs across different generations and trends in their use over the 20th and 21st centuries. MATERIALS AND METHODS: A retrospective observational cohort study was conducted in 2022–2024. Study population: patients with a verified diagnosis of epilepsy. Study focus: antiepileptic drug therapy. Patients with a verified diagnosis of epilepsy were divided into 2 groups: group 1 included patients from the 20th century with epilepsy duration of more than 20 years as of 2020; group 2 included patients from the 21st century with epilepsy duration of less than 20 years. The history of antiepileptic drugs use was evaluated by generation: first-generation (traditional/older), second-generation (newer), and third-generation (most recent). The frequency of first-generation antiepileptic drugs use was calculated both as a percentage and as the mean number of antiepileptic drugs per patient for the 20th and 21st centuries. RESULTS: The study included 60 patients: group 1 comprised 28 patients and group 2, 32 patients. The mean age and disease duration in the overall cohort were 31.5±9.3 years and 19.5±9.1 years, respectively; the male-to-female ratio was 1:1. The mean number of antiepileptic drugs used per patient over time was 5.1±2.3 (range, 2–10). First-generation antiepileptic drugs were used in 61% of patients in group 1 and 42% in group 2; second-generation in 32% and 46%, respectively; and third-generation in 7% and 12%, respectively. The mean number of first-generation antiepileptic drugs per patient across the cohort was 2.2±1.5, with group-specific means of 3.1 in group 1 and 1.3 in group 2. Barbiturates accounted for 24% of prescriptions in group 1 and 5% in group 2; benzodiazepines, for 5% and 0%, respectively; valproates, for 26% in both groups; and carbamazepine, for 13% and 8%, respectively. CONCLUSION: An increased use of newer-generation antiepileptic drugs (anticonvulsants) was observed in the 21st century, with a marked decline in older-generation drugs, primarily due to decreased use of barbiturates and benzodiazepines. Valproic acid and carbamazepine have maintained their roles in epilepsy management.

Authors

Institutions

Publication Details

Journal
Russian Military Medical Academy Reports
Published
2025-05-25
DOI
https://doi.org/10.17816/rmmar635899
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Trends in Antiepileptic Drug Use in Pharmacoresistant Epilepsy

N. O. Dengina, Г. В. Одинцова, Н. Е. Иванова
Russian Military Medical Academy Reports
Epilepsy research and treatment
article

Trends in Antiepileptic Drug Use in Pharmacoresistant Epilepsy

N. O. Dengina, Г. В. Одинцова, Н. Е. Иванова
article en

Abstract

Background: Antiepileptic drugs are the cornerstone of treatment in patients with epilepsy. AIM: to examine the spectrum of antiepileptic drugs across different generations and trends in their use over the 20th and 21st centuries. MATERIALS AND METHODS: A retrospective observational cohort study was conducted in 2022–2024. Study population: patients with a verified diagnosis of epilepsy. Study focus: antiepileptic drug therapy. Patients with a verified diagnosis of epilepsy were divided into 2 groups: group 1 included patients from the 20th century with epilepsy duration of more than 20 years as of 2020; group 2 included patients from the 21st century with epilepsy duration of less than 20 years. The history of antiepileptic drugs use was evaluated by generation: first-generation (traditional/older), second-generation (newer), and third-generation (most recent). The frequency of first-generation antiepileptic drugs use was calculated both as a percentage and as the mean number of antiepileptic drugs per patient for the 20th and 21st centuries. RESULTS: The study included 60 patients: group 1 comprised 28 patients and group 2, 32 patients. The mean age and disease duration in the overall cohort were 31.5±9.3 years and 19.5±9.1 years, respectively; the male-to-female ratio was 1:1. The mean number of antiepileptic drugs used per patient over time was 5.1±2.3 (range, 2–10). First-generation antiepileptic drugs were used in 61% of patients in group 1 and 42% in group 2; second-generation in 32% and 46%, respectively; and third-generation in 7% and 12%, respectively. The mean number of first-generation antiepileptic drugs per patient across the cohort was 2.2±1.5, with group-specific means of 3.1 in group 1 and 1.3 in group 2. Barbiturates accounted for 24% of prescriptions in group 1 and 5% in group 2; benzodiazepines, for 5% and 0%, respectively; valproates, for 26% in both groups; and carbamazepine, for 13% and 8%, respectively. CONCLUSION: An increased use of newer-generation antiepileptic drugs (anticonvulsants) was observed in the 21st century, with a marked decline in older-generation drugs, primarily due to decreased use of barbiturates and benzodiazepines. Valproic acid and carbamazepine have maintained their roles in epilepsy management.

Russian Military Medical Academy ReportsVol. 44(1)
Russian Scientific Research Neurosurgical Institute (RU), Ministry of Health of the Russian Federation (RU)
Openalex Percentile: Top 86%
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.